Despite what it sees as improvements across multiple regulatory fronts over the past few years, Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) says “there still exists room for improvement” to increase the number of new drug approvals it issues ahead of any other country.
In a new activity update, chief executive Yasuhiro Fujiwara points out that the number of such clearances has already been increasing slightly over the past few years, but